Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
Baxter
AstraZeneca
Express Scripts

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,403,381

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 6,403,381
Title: Inhibition of coagulation in blood and blood products
Abstract:The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.
Inventor(s): Mann; Kenneth G. (Grand Isle, VT), Rand; Mathew D. (Danvers, MA), Cawthern; Kevin M. (Haverstraw, NY)
Assignee: University of Vermont and State Agriculture College (Burlington, VT)
Application Number:09/327,806
Patent Claims:1. A method for assaying clotting in plasma, the method comprising:

a) treating blood with a solution comprising an amount of a calcium-chelating agent sufficient to inhibit clotting,

b) subjecting the blood to conditions conducive to producing plasma,

c) freezing the plasma,

d) contacting the frozen plasma with an amount of corn trypsin inhibitor (CTI) sufficient to inhibit clotting,

e) thawing the frozen plasma,

f) recalcifying the thawed plasma; and

g) assaying the clotting in the plasma,

wherein the plasma is isolated from a patient who has or is suspected of having a blood coagulation disorder selected from the group consisting of hemostatic or thrombotic abnormality, coagulation inhibitor deficiency, and a disseminated intravascular condition.

2. The method of claim 1, wherein the plasma is obtained from a patient who has or is suspected of having a deficiency in at least one blood coagulation factor.

3. The method of claim 1, wherein the patient is in need of anti-coagulant therapy.

4. The method of claim 1, wherein the patient was subjected to or is in need of an invasive surgical procedure.

5. A method for assaying clotting in plasma, the method comprising the steps of:

a) treating blood with a solution comprising an anti-coagulation effective amount of corn trypsin inhibitor (CTI) and a calcium chelating agent,

b) subjecting the blood to conditions conducive to producing plasma,

c) recalcifying the plasma; and

d) assaying the clotting in the recalcified plasma,

wherein the plasma is isolated from a patient who has or is suspected of having a blood coagulation disorder selected from the group consisting of hemostatic or thrombotic abnormality, coagulation inhibitor deficiency, and a disseminated intravascular condition.

6. The method of claim 5, wherein the plasma is obtained from a patient having or suspected of having a deficiency in at least one blood coagulation factor.

7. The method of claim 5, wherein the patient has been subjected to or is in need of an invasive surgical procedure.

8. The method of claim 5, wherein the blood coagulation disorder is hemophilia A, B or C type.

9. A method for monitoring blood coagulation, the method comprising contacting a blood sample with an amount of corn trypsin inhibitor (CTI) sufficient to reduce or eliminate blood coagulation; and monitoring the coagulation of the blood sample, wherein the monitoring comprises measuring the blood coagulation, and the blood sample comprises at least one of a fibrinolytic, antithrombotic, or antiplatelet agent.

10. The method of claim 9, wherein the blood is obtained from a human patient who has or is suspected of having a platelet deficiency or abnormality.

11. The method of claim 9, wherein the blood sample further comprises relipidated tissue factor.

12. The method of claim 11, wherein the blood sample comprises hirudin, tick anticoagulant peptide, abciximab, heparin or enoxaparin.

13. A method for inhibiting clotting of an uncalcified blood product, the method comprising adding corn trypsin inhibitor (CTI) to the uncalcified blood product in an amount sufficient to inhibit the clotting, the blood product being plasma and the inhibition being by contact initiation, wherein the plasma is isolated from a patient who has or is suspected of having a blood coagulation disorder selected from the group consisting of hemostatic or thrombotic abnormality, coagulation inhibitor deficiency, and a disseminated intravascular condition.

14. The method of claim 13, wherein the disseminated intravascular condition is associated with an autoantibody capable of binding a coagulation factor.

15. The method of claim 13, wherein the patient has been or will be subjected to an invasive surgical procedure.

16. A method for inhibiting clotting of a blood product, the method comprising adding corn trypsin inhibitor (CTI) to the blood product in an amount sufficient to inhibit the clotting, the blood product being plasma and the inhibition being by contact initiation, wherein the plasma is isolated from a patient who has or is suspected of having a blood coagulation disorder selected from the group consisting of hemostatic or thrombotic abnormality, coagulation inhibitor deficiency, and a disseminated intravascular condition, wherein the patient has been or will be subjected to an invasive surgical procedure.

17. A method for inhibiting clotting of a blood product, the method comprising adding corn trypsin inhibitor (CTI) to the blood product in an amount sufficient to inhibit the clotting, the blood product being plasma and the inhibition being by contact initiation, wherein the plasma is isolated from a patient who has or is suspected of having a blood coagulation disorder which is hemophilia A, B or C type.

Details for Patent 6,403,381

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial University of Vermont and State Agriculture College (Burlington, VT) 2018-06-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
Colorcon
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.